Navigation Links
New investigational compound targets pancreatic cancer cells
Date:9/15/2010

SCOTTSDALE, Ariz. (Sept. 14, 2010) A new investigational drug designed to penetrate and attack pancreatic cancer cells has been administered to a patient for the first time ever at the Virginia G. Piper Cancer Center at Scottsdale Healthcare.

ASG-5ME is a potent, targeted compound designed to selectively kill cancer cells, says Daniel Von Hoff, MD, a principal investigator in the Phase I clinical trial. Pancreatic cancer is a fast-growing and difficult to treat form of cancer, and is the fourth leading cause of cancer death in the United States.

"ASG-5ME is intended for pancreatic cancer patients who do not have a good prognosis with currently available therapies. We are very pleased to be able to offer this exciting agent in a clinical trial for patients with advanced pancreatic cancer," says Dr. Von Hoff. "Our goal at the Virginia G. Piper Cancer Center is to deliver cell-killing medicine through the best possible individually targeted therapies, and ASG-5ME fits the bill."

The new investigational compound uses a monoclonal antibody against a target which is found in more than 90 percent of pancreatic cancer patients. The monoclonal antibody delivers a highly potent molecule called monomethyl auristatin E (MMAE) to selectively kill the pancreatic cancer cells.

"It is a precision approach that is designed to avoid non-targeted cells, increasing antitumor activity in preclinical models and potentially reducing the toxic effects of traditional chemotherapy" says Dr. Von Hoff. Researchers are studying the drug to evaluate its safety and tolerability and identify the maximum tolerated dose.

The Virginia G. Piper Cancer Center at Scottsdale Healthcare was the first to offer patient access to ASG-5ME. Researchers hope to enroll up to 50 patients in clinical trials of the drug in multiple centers across the U.S.

The drug was co-developed by Seattle Genetics, Inc. of Bothell, Wash. and Agensys, Inc., an affiliat
'/>"/>

Contact: Keith Jones
kjones@shc.org
480-882-4412
Scottsdale Healthcare
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Pivotal data for the investigational treatment PSD502 for primary premature ejaculation
2. Scott & White Healthcare researchers studying investigational agent that targets breast cancer
3. Compounds in non-stick cookware may be associated with elevated cholesterol in children and teens
4. Plant compound resveratrol shown to suppresses inflammation, free radicals in humans
5. Breast cancer cells regulate multiple genes in response to estrogen-like compounds
6. Concentration, timing and interactions are key when it comes to dietary compounds
7. Compound enhances cancer-killing properties of agent in trials
8. Researchers find compound effective in destroying antibiotic-resistant biofilms
9. New pyrimidine compounds may lead to improved treatments for childhood brain cancer
10. Chemotherapy plus synthetic compound provides potent anti-tumor effect in pancreatic cancers
11. Sigma-Aldrich Reaches Agreement to Sell Pfizers Bioactive Small Molecule Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... (PRWEB) May 04, 2015 During 2015-2019, ... a 7.7% CAGR. Currently, the European and APAC probiotic ... while the North American probiotic market lags behind owing ... population. , The North American probiotic market is ... 58%), followed by Canada and Mexico. The North American ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Malibu ... oral antiseptic breath spray. KissSafe™ is the first ... a safer experience while adding fresh breath appeal. ... and effectively kills germs in the mouth and ... also contains ingredients that possess additional wellness benefits. ...
(Date:5/4/2015)... 04, 2015 In a continuing effort ... substance absue, Per Wickstrom, the founder of Choices Recovery ... and the “Salute to the Oscars” celebration held ... the top floor of the luxurious Beverly Hilton Hotel. ... producer of sustainable product placement in TV and film, ...
(Date:5/4/2015)... New York (PRWEB) May 04, 2015 ... as $2.4 billion to settle thousands of Actos lawsuits ... diabetes medication increases the risk that a patient will ... on April 28th, if 95% of those eligible for ... resolve nearly 9,000 bladder cancer cases currently pending in ...
(Date:5/4/2015)... 2015 Getting patients to work with ... is critical to achieving the “triple aim” of better ... this will require a shift in thinking from stakeholders ... health systems move beyond their traditional boundaries to reach ... the third live meeting of the ACO and ...
Breaking Medicine News(10 mins):Health News:North America Probiotic Market to Increase by 2019, Announces MicroMarketMonitor in Its New Research Report Recently Published at MarketPublishers.com 2Health News:80 Million Germs from Kissing - Introducing KissSafe™ 2Health News:Per Wickstrom Interviews TV and Film Star Carolyn Hennesy About Substance Abuse and Treatment 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 3Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 2Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 3Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 4
... in collaboration with,Siemens(R), AxisThree(R), Inc. of Pacific Palisades, ... Technology into the,Plastic Surgery office of Dr. Steve ... XS-300(TM), is the first of its kind, and ... combined with,innovative proprietary software. The XS-300(TM) platform photographs ...
... launch of its redesigned web site at www.oci.com , ... ... to meet the needs of its customers and target market, OCI is ... The site features improved content, an enhanced look and feel, and easy ...
... percent savings on medical services and healthcare products. , ... ... -- Allsup announced today it is offering a new http://www.allsup.com/Health-Discount-Program.aspx/?=PRJ2 ... of people with disabilities gain access to discounted healthcare and ...
... prescription drug samples distributed to children may be unsafe, ... Alliance and Hasbro Children,s Hospital. The national study, the ... children, appears in the October 2008 issue of ... as researchers at Harvard Medical School and the Warren ...
... long way toward helping severely obese individuals improve their ... to researchers at the Duke Diet and Fitness Center. ... average, just under one hour of exercise per week, ... life. They also reported improvements in their ability to ...
... Extendicare Skilled Nursing Facilities Named In Wash. Lawsuit, ... with,additional allegations in the class action lawsuit against ... the state of Washington [see,list by city at ... in,United States District Court, Western Washington Division, in ...
Cached Medicine News:Health News:Plan Your Breasts in 3-D 2Health News:Information Management Solutions Provider OCI Announces Redesign of Corporate Web Site 2Health News:Allsup Introduces Health Discount Program to Millions of People with Disabilities 2Health News:Allsup Introduces Health Discount Program to Millions of People with Disabilities 3Health News:Free drug samples carry risks for children 2Health News:A little exercise goes a long way for severely obese 2Health News:Additional Allegations Filed Against Elder Care Operator 2Health News:Additional Allegations Filed Against Elder Care Operator 3Health News:Additional Allegations Filed Against Elder Care Operator 4Health News:Additional Allegations Filed Against Elder Care Operator 5
(Date:5/4/2015)... Calif., May 4, 2015  Xencor, Inc. (NASDAQ: ... engineered monoclonal antibodies for the treatment of autoimmune ... reported financial results for the first quarter ended March ... highlights. "Following our equity offering in ... million, we are in a strong financial position ...
(Date:5/4/2015)... , May 4, 2015 PTC Therapeutics, Inc. (NASDAQ: ... financial results for the first quarter ending March 31, 2015. ... this year. In our first full quarter since the commercial ... the first treatment for nonsense mutation Duchene Muscular Dystrophy. We ... number on treatment since our last earnings call," stated ...
(Date:5/4/2015)... Pa. , May 4, 2015 DePuy ... Dura Repair, the first commercially available biosynthesized dural ... Synthes CMF is a part of the DePuy Synthes ... is a tissue membrane that covers and protects the ... be cut to allow surgeons to access the brain. ...
Breaking Medicine Technology:Xencor Reports First Quarter 2015 Financial and Operating Results 2Xencor Reports First Quarter 2015 Financial and Operating Results 3Xencor Reports First Quarter 2015 Financial and Operating Results 4Xencor Reports First Quarter 2015 Financial and Operating Results 5Xencor Reports First Quarter 2015 Financial and Operating Results 6Xencor Reports First Quarter 2015 Financial and Operating Results 7Xencor Reports First Quarter 2015 Financial and Operating Results 8PTC Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update 9DePuy Synthes CMF Launches First Biosynthesized Cellulose-Based Dural Replacement For Neurosurgery 2DePuy Synthes CMF Launches First Biosynthesized Cellulose-Based Dural Replacement For Neurosurgery 3
... 20, 2011 One of Frantz Medical Group,s (FMG) ... has been awarded an Ohio Third Frontier grant to ... for penetrating through vascular Chronic Total Occlusions (CTOs), in ... Artery Bypass Graft (CABG).   VasoStar,s primary ...
... Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, ... Board and Chief Scientific Officer, will participate on a ... Conference on July 22nd, 2011, 10:30 am ET. The ... in Washington, D.C. on July 20-22, 2011, and will ...
Cached Medicine Technology:Frantz Medical Group Subsidiary, VasoStar, Awarded $1 Million Research Grant 2Frantz Medical Group Subsidiary, VasoStar, Awarded $1 Million Research Grant 3Chimerix to Present at Infocast's 9th Annual Biodefense Vaccines & Therapeutics Conference 2Chimerix to Present at Infocast's 9th Annual Biodefense Vaccines & Therapeutics Conference 3
... the only in-office test approved by the FDA ... BladderChek Test is a painless and non-invasive assay, ... elevated levels of NMP22 protein. Healthy individuals generally ... the urine. However, the level of NMP22 protein ...
Used for measuring rectal pressure during urodynamic studies. All-silicone construction provides maximum softness and biocompatibility for enhanced patient comfort. Supplied sterile in peel-open pack...
Used for suprapubic monitoring of bladder pressures. Suprapubic urodynamic studies avoid the effects of urethral catheterization and eliminate the need for a double bladder puncture. Supplied sterile...
... point-of-care (POC) diagnosis of patients with acute ... embolism. For use in doctors offices or ... counts, the Cardiac reader analyzer allows the ... D-Dimer from a single whole blood sample ...
Medicine Products: